Horvath, N.
2 papers on CoChatORCID 0000-0001-9600-1275
Most cited papers
- Verified
Response of myeloma to the proteasome inhibitor bortezomib is correlated with the unfolded protein response regulator XBP-1
Ling, S. C. W., Lau, E. K. K., Al-Shabeeb, A., Nikolic, A., Catalano, A., Iland, H., Horvath, N., Ho, P. J., Harrison, S., Fleming, S., et al. (2012) · Haematologica
Multiple Myeloma Research and TreatmentsEndoplasmic Reticulum Stress and Disease
Cited by 130
- Verified
Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial
Dimopoulos, M. A., Richardson, P. G., Bahlis, N. J., Grosicki, S., Cavo, M., Beksaç, M., Legieć, W., Liberati, A. M., Goldschmidt, H., Belch, A., et al. (2022) · The Lancet Haematology
Multiple Myeloma Research and TreatmentsBone health and treatments
Cited by 48
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free